ABOUT
Neuro-Bio is a privately owned biotech, spun out of Oxford University, with a therapeutic focus on neurodegenerative disease. The company has discovered a novel molecule (T14) which is toxic in the adult brain and shown to be a potential key driver of neurodegeneration.
This distinct mechanism is utilised by Neuro-Bio to develop exciting new drugs to treat Alzheimer’s disease (AD), alongside a biomarker which can diagnose AD prior to the onset of symptoms.
A DISRUPTIVE APPROACH
The disruptive approach of Neuro-Bio has:
- Identified the subset of cells vulnerable to Alzheimer’s disease (AD)
- Explained the reason they are prone to degenerate
- Identified the key pivotal toxic peptide (‘T14’) driving this process
- Proved that T14 is a feature of the AD brain
- Developed a novel animal model based on T14
- Devised a possible test whereby T14 could be a biomarker of AD
- Identified the T14 target receptor
- Designed a T14 blocker as an effective therapeutic drug for AD, with proven behavioural and histological effects
Testimonial
“Prof. Greenfield and her colleagues at Neuro-Bio have developed a novel, innovative, and potentially very fruitful approach to the treatment of Alzheimer’s disease.
The work represents an excellent example of translational research in which a finding in basic neurobiology has been linked to key aspects of human disease.” Dr Richard Mohs, Chief Scientific Officer for the Global Alzheimer’s Platform (GAP) Foundation.